NEWS RELEASE

Teijin Pharma and SRETT Sign Exclusive Distribution

Agreement for Respiratory Remote-monitoring Device

Tokyo, Japan, Oct 16, 2017 --- Teijin Pharma Limited, the core company of the Teijin
Groups healthcare business, and SRETT, a French IoT provider, announced today they
have agreed to an exclusive distribution arrangement in Japan for TeleOx, a device
developed by SRETT which remotely monitors patients respiratory functions in
oxygen therapy.

TeleOx is a compact device with a diameter of 46mm and low weight of 34 grams,
integrated with the oxygen cannula to measure patients respiratory rate and oxygen
flow rate even during oxygen inhalation. TeleOx is Bluetooth Smart-enabled device
and compatible with various systems, furthermore it can store the conditions of use for
two years in built-in memories. This small device is compatible with Hi-Sanso3S,
Hi-Sanso5S by Teijin Pharma, and will be launched in April 2018 in Japan. Teijin
Pharma plans to provide rental service for medical institutions, aiming for leveraging
TeleOx for patient instruction and management.

TeleOx Image

Since 1991, Teijin Pharma has been selling systems which monitor the operating status
and oxygen flow settings of home oxygen concentrators and then providing this
information to healthcare providers via telephone networks. However, since these
systems do not monitor how much time patients have actually absorbed oxygen. Teijin
Pharma acquired the exclusive distribution rights of TeleOx in Japan from SRETT with
the aim of solving existing problems and promoting more appropriate use of home
oxygen therapy by introducing TeleOx which can detect the situation of oxygen
inhalation at home.

Teijin Pharma will launch newly advanced oxygen-monitoring services incorporating

TeleOx. The services are planned to be offered to medical institutions in April 2018.
By developing next-generation services for home oxygen therapy, SRETT and Teijin
Pharma look forward to contributing to improved home care in Japan.

About SRETT
Founded in 2004 in France, SRETT is an innovative IoT technology company which has
become a leading provider of solutions for both industry and healthcare fields.

In the past decade, SRETT has been committed to leveraging connected equipment so
that professionals can preserve their resources and optimize their operations. The
company has supplied over 200 000 connected objects in 17 countries, notably for oil &
gas, tracking, and healthcare, and processes daily more than 5 million new individual
pieces of data.

SRETT is active in the field of homecare patient remote monitoring, for which it has
developed a comprehensive range of solutions for chronic respiratory disease
management. Already successful in Europe since 2012 in telemonitoring of CPAP
therapy in sleep apnea patients, the company has engaged to offer new perspectives in
treatment of COPD and comorbidities with easy to deploy IoT solutions.
For more information, please visit www.srett.com

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the
areas of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Its main fields of operation are
high-performance fibers such as aramid, carbon fibers & composites, healthcare, films,
resin & plastic processing, polyester fibers, products converting and IT. The group has
some 170 companies and around 19,000 employees spread out over 20 countries
worldwide. It posted consolidated sales of JPY741.3 billion (USD 6.5 billion) and total
assets of JPY 964.1 billion (USD 8.5 billion) in the fiscal year ending March 31, 2017.
Please visit www.teijin.com

Press Contact
Corporate Communications
Teijin Limited
+81 3 3506 4055
pr@teijin.co.jp